Evidence map›Paper›PMID 38796792›Full record

ArticleDermatology and therapy2024

Efficacy and Safety of Oxymatrine in the Treatment of Patients with Erythrodermic Psoriasis.

Huijuan Shi, Dongmei Chen, Jiawei Si, Qian Zou, Yatao Guo, Jiayu Yu, Cheng Li, Fang Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Dermatology and therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Huijuan ShiInnovation Team for Skin Disease Diagnosis and Treatment Technology and Drug Discovery and Development, Department of Dermatovenereology, General Hospital of Ningxia Medical University, 804 Shengli South Street, Yinchuan, 750004, Ningxia, China. shjyjm@163.com.ORCID http://orcid.org/0000-0002-2998-1637
Dongmei ChenInnovation Team for Skin Disease Diagnosis and Treatment Technology and Drug Discovery and Development, Department of Dermatovenereology, General Hospital of Ningxia Medical University, 804 Shengli South Street, Yinchuan, 750004, Ningxia, China.
Jiawei SiClinical Medical School, Ningxia Medical University, Yinchuan, 750004, Ningxia, China.
Qian ZouClinical Medical School, Ningxia Medical University, Yinchuan, 750004, Ningxia, China.
Yatao GuoClinical Medical School, Ningxia Medical University, Yinchuan, 750004, Ningxia, China.
Jiayu YuClinical Medical School, Ningxia Medical University, Yinchuan, 750004, Ningxia, China.
Cheng LiClinical Medical School, Ningxia Medical University, Yinchuan, 750004, Ningxia, China.
Fang WangClinical Medical School, Ningxia Medical University, Yinchuan, 750004, Ningxia, China.

Funding

Key Technologies Research and Development Program of ningxia No. 2019BFG02008National Natural Science Foundation of China 82060572
6 · The paper itself

Abstract

introductionThe management of erythrodermic psoriasis (EP), a rare but severe type of psoriasis, is challenging, especially in patients with concomitant chronic hepatitis B (CHB). We previously demonstrated that oxymatrine treatment alleviated severe plaque psoriasis, but its therapeutic potential in treating EP remains unexplored. This study was to assess the efficacy and safety of oxymatrine for the treatment of EP, with attention to concomitant CHB.

methodsIn this investigator-initiated clinical trial, four consecutive patients with EP, including two (A and B) with concomitant CHB, were treated with intravenous administration of oxymatrine as monotherapy for 8 weeks, and scheduled to be followed up for a minimum of 24 weeks. The primary outcome was at least 75% improvement in the psoriasis area and severity index (PASI 75) at week 32. Secondary outcomes included the body surface area (BSA) score, dermatology life quality index (DLQI)], and safety.

resultsPatients A, B, and C achieved PASI 75 at treatment completion and week 32, demonstrating improvements of 77.4%, 97.2%, and 100% in PASI, respectively. Their BSA and DLQI were also improved significantly at week 32 and throughout follow-up of 37, 57, and 105 weeks, respectively. The viral loads in patients A and B with CHB decreased modestly. Patient D discontinued after follow-up for 19 weeks, and the primary outcome could not be analyzed. No adverse events were reported during treatment and follow-up.

conclusionOxymatrine appears to be efficacious and safe for the treatment of patients with EP, including those with concomitant CHB.

trial registrationThis study was registered at the Chinese Clinical Trial Registry ( www.chictr.org.cn ; Registration number ChiCTR-TRC-14004301).

Indexed as

AlkaloidChronic hepatitis BCytokinesErythrodermic psoriasisHepatitis B virusOxymatrinePsoriasis

Identifiers

PMID38796792
PMCPMC11169162

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.